clinical trial · NCT07165886
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·phase3·recruiting·n = 298
Gastroenteropancreatic Neuroendocrine TumorsSirolimus for injection (albumin bound)Octreotide long-acting injectionEverolimus
brief summary
There is limited evidence regarding the benefit of adding somatostatin analogs to molecular targeted agents for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with poor prognostic factors. This trial is conducted to evaluate sirolimus for injection (albumin bound) combined with octreotide long-acting injection in patients with unresectable or recurrent GEP-NETs.
started
Aug 29, 2025
primary completion
Aug 29, 2028
completion
Aug 29, 2028
last updated
Apr 24, 2026
official title
Phase II/III Study to Evaluate the Safety and Efficacy of Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol